Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2023
>
Roche, Boehringer tap biosensor firms for patient studies
Roche, Boehringer tap biosensor firms for patient studies
Read also
Alnylam plans $250m
Alnylam plans $250m investment in Norton manufacturing facility, US
EC approves Incyte’s Minjuvi
EC approves Incyte’s Minjuvi combo for follicular lymphoma
How AI May Revolutionize the Pharmaceutical Industry
Many companies and businesses have viewed artificial intelligence (AI) as a tool for amplifying efficiency, such as automating simple tasks and making backend projects more efficient.
TSC Alliance Endowment Fund Invests
TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex
